Search

Author/Creator Papadatos-Pastos, D.

1. 339 Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit (DDU) of the Royal Marsden Hospital (RMH). (September 2015)

Authors:
Papadatos-Pastos, D.; Roda, D.; Luken, M. De Miguel; Jalil, A.; Diamantis, N.; Michalarea, V.; Lima, J.; Capelan, M.; Bodla, S.; Bhosle, J.; Molife, R.; O'Brien, M.; Banerji, U.; Popat, S.; Yap, T.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S67
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Evaluation of membrane type 1 metalloproteinase (MT1-MMP/MMP14) expression as a prognostic biomarker in patients with solid tumours screened for a Phase I/II trial. (October 2022)

Authors:
Peters, N.; Morley, H.; Khalique, S.; Scalzo, S.; Patel, R.; Gunaydin, U.; Funingana, G.; Evans, J.; Papadatos-Pastos, D.; Banjeri, U.; Basu, B.; Niewiarowski, A.; Symeonides, S.; Kelly, F.; Sawretse, L.; Bacon, C.; Robinson, M.; Gelb, T.; Blakemore, S.; Cook, N.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S117
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗